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The cloning of the mouse PPAR alpha gene in 1990 by
Issemann and Green [1] stimulated intense interest in this
family of nuclear receptors, and research eﬀorts over the next
decade established important roles for the PPAR isotypes
in glucose and lipoprotein metabolism, inﬂammation, and
atherosclerosis. Though the ﬁbrates (PPAR-α agonists) had
been used for the treatment of dyslipidemia for nearly
40 years, the discovery of the insulin-sensitizing eﬀects
of PPAR-γ agonists brought about the development and
commercialization of the thiazolidinedione (TZD) class of
oral anti-hyperglycemic medications: troglitazone, approved
by the FDA in 1997, and pioglitazone and rosiglitazone, both
approvedbytheFDAin1999.Thewithdrawaloftroglitazone
from the market in 2000 was an early indicator of the
potentialsafetyissuesofPPARdrugs.Evenso,theclinicaluse
of ﬁbrates and TZDs has allowed for a better understanding
of the safety proﬁles and safety issues of PPAR-α and PPAR-γ
agonists [2, 3].
At the beginning of this decade, many pharmaceutical
companieshaddevelopmentprogramsfocusedondelivering
“new and improved” PPAR agonists to the market. For
example, several programs were developing PPAR-α/γ dual
agonists (i.e., glitazars) for the treatment of type 2 diabetes.
Although preliminary data from various PPAR-α/γ dual
agonist research programs was promising, nearly all of these
research programs were discontinued due to safety issues
identiﬁed during clinical testing and/or during preclinical
testing [4–6]. More recently, the highly publicized (and
controversial) meta-analysis of rosiglitazone reported by
Nissen and Wolski [7] called into question the safety of
the TZDs and prompted changes to the labels of both
rosiglitazone and pioglitazone.
And yet, the promise of the therapeutic potential of
PPAR drugs remains. A PubMed search using the term
“peroxisome proliferator-activated receptor” yielded 1578
manuscripts (161 of which were review articles) between
January 1 and December 1, 2008. In addition to the roles of
the PPAR isotypes in lipid/lipoprotein/glucose metabolism,
additionalrolesindiversephysiologicalprocessesanddisease
states are currently being investigated. As additional func-
tions are identiﬁed; the PPARs will continue to be impor-
tant molecular targets for identifying ligands (drugs) with
potential applications to reproduction and fertility, normal
development; function of the reproductive, gastrointestinal,
respiratory, and central nervous systems; skin biology and
wound healing; and cell cycle control and cancer.
Reports highlighting both challenges and opportunities
in PPAR drug development are included in this special
issue. For example, edema, weight gain, and a reduction
in bone mass (particularly in women) are challenges lim-
iting the clinical utility of the currently marketed TZDs.
The renal and vascular mechanisms of TZD-induced ﬂuid
retention are reviewed by Yang and Soodvilai, and the recent
clinical data describing the eﬀects of TZDs on bone are
reviewed by Schwartz. In contrast, several reports highlight
opportunities in PPAR drug development. Deeg and Tan
compare the eﬀects of rosiglitazone and pioglitazone on
lipids, lipoproteins, and apolipoproteins as reported in head-
to-head, randomized clinical studies. Two papers describe
theeﬀectsofPPARs/PPARligandsonimmune/inﬂammatory
responses; Fernandez reviews the roles of the PPARs in mod-
ulating the immune/inﬂammatory response in atherosclero-
sis, while Yamashita reviews the receptor-independent eﬀects
of PPAR-α and PPAR-γ ligands on cysteinyl leukotriene
production in mast cells as it relates to the development
of potential anti-asthma medications. Technological and
methodological approaches that may prove useful in the
identiﬁcation and assessment of new PPAR drugs are2 PPAR Research
also reported. Clarke et al. describe an approach used to
determine the species diﬀerences in plasma protein binding
to MBX-102, a novel PPAR-γ agonist currently in Phase 2
clinical development, and the corresponding diﬀerences in
PPAR-γ activation across species. Cho et al. review the role
of PPARs in metabolic disorders as well as various strategies
and technologies used in the identiﬁcation and assessment
of PPAR drugs. Finally, Miyachi and Hashimoto describe
the synthesis and SAR of subtype-speciﬁc PPAR agonists
derivedfromasingle3,4-disubstitutedphenylpropanoicacid
“versatile template” scaﬀold, and Higgins and Mantzoros
review the development and safety proﬁle of INT-131,
a potent non-TZD selective PPAR modulator (SPPARM)
currently in Phase 2 clinical development.
In conclusion, though the full therapeutic potential of
PPARs has yet to be realized, and serious safety issues are
associated with the currently marketed PPAR drugs (PPAR-α
andPPAR-γ),thereremainsintenseinterestinexploringnew
physiological roles of the PPARs and in the identiﬁcation of
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